Edorium Journal of

Pediatrics

 
     
Original Article
 
Soluble urokinase plasminogen activator receptor (suPAR) is prospective biomarker to evaluate treatment progress in children with pulmonary tuberculosis during maintenance phase
Mardining Raras Tri Yudani1, Marrecar Aunilla Hamid2, Muhammad Slamet Chandra Kusuma3, Ery Olivianto4
1Dr.rer.nat, Associate Professor, Department of Biochemistry and Molecular Biology, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia
2MD, Master Program on Biomedical Science, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia
3Professor, Dr, MD, Professor, Pediatric Department, Dr Saiful Anwar Hospital, Malang, Indonesia
4MD, Pediatrican, Pediatric Department Dr Saiful Anwar Hospital, Malang, Indonesia

Article ID: 100002P05MY2017
doi:10.5348/P05-2017-2-OA-2

Address correspondence to:
Mardining Raras Tri Yudani
Dr.rer.nat, Department of Biochemistry and Molecular Biology
Faculty of Medicine, Brawijaya University, Malang
Jawa Timur, Indonesia

Access full text article on other devices

  Access PDF of article on other devices

[HTML FULL TEXT]   [PDF Full Text] [Print This Article]
[Similar article in Pumed] [Similar article in Google Scholar]

How to cite this article
Tri Yudani MR, Hamid MA, Kusuma MSC, Olivianto E. Soluble urokinase plasminogen activator receptor (suPAR) is prospective biomarker to evaluate treatment progress in children with pulmonary tuberculosis during maintenance phase. Edorium J Pediatr 2017;1:6–11.


ABSTRACT
Aims: Childhood pulmonary tuberculosis (TB) is still a major problem in developing countries. One of the difficulty in TB management is lack of biomarkers to evaluate treatment response.This study aimed to investigate the role of plasma soluble urokinase-type plasminogen activator receptor (suPAR) as a biomarker to evaluate response to anti tuberculosis treatment in children with pulmonary TB.
Methods: Twenty five children aged 2–10 years with pulmonary TB in Dr Saiful Anwar Hospital, Malang from February 2012 to January 2013 were enrolled into the study. The plasma suPAR level was measured using ELISA prior to anti-tuberculosis treatment and two, four, six months after treatment initiation. Clinical parameters were observed including coughs, lymphadenitis, nutritional status and X-ray. Ten healthy children served as a control group.
Result: All TB patients showed high plasma suPAR levels prior to anti TB treatment (4.77 +1.51 ng/mL) and did not change (p = 0.0001>0.05) after two months (4.89+1.61 ng/mL) of treatment. However, it decreased significantly after four months (2.51+1.81 ng/mL) and six months of treatment (0.27+0.64 ng/mL). By the end of therapy the level of suPAR reached a value that was lower than control group (1.58+0.09 ng/mL). The reduce of suPAR level was not parallel to clinical improvement after two months treatment.
Conclusion: the suPAR level is elevated in childhood pulmonary TB and significantly decreased after four months of anti tuberculosis treatment. This imply that suPAR is not appropriate biomarker to evaluate TB treatment response in childhood TB after intensive phase of therapy. However, it is a prospective biomarker to monitor the efficacy of therapy in the maintenance phase after two months therapy.

Keywords: Biomarker, Children, Pulmonary tuberculosis, Soluble urokinase plasminogen activator receptor (suPAR)

[HTML FULL TEXT]   [PDF Full Text]

Acknowledgements
We thank to Fitri Armania from Laboratory Biochemistry and Molecular Biology, Faculty of Medicine, Brawijaya University for technical support. Our special gratitude to suPARnosticò, ViroGates A/S, Copenhagen, Denmark for kit discount.

Author Contributions
Mardining Raras Tri Yudani – Substantial contributions to conception and design, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Marrecar Aunilla Hamid – Acquisition of data, Analysis and interpretation of data, Drafting the article, Final approval of the version to be published
Muhammad Slamet Chandra Kusuma – Substantial contributions to conception and design, Revising it critically for important intellectual content, Final approval of the version to be published
Ery Olivianto – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Guarantor of submission
The corresponding author is the guarantor of submission.
Source of support
None
Conflict of interest
Authors declare no conflict of interest.
Copyright
© 2017 Mardining Raras Tri Yudani et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.



  Home line About the Journal line Aim and Scope line Sections line Open Access line Archives
Apply as Editor line Apply as Reviewer line Submit Reviews - Editors line Submit Reviews - Reviewers
Instructions for Authors line Templates to Use line Copyright Form line Author Checklist
Online Submission line Email Submission line Submit Revision line Submit All Forms line Submit Page Proofs
Terms of Service line Privacy policy line Disclaimer line FAQ line Contact: Journal line Contact: Edorium Journals line Site Map
 
  Copyright © 2017. Edorium. All rights reserved.